Winston & Strawn has deep expertise in handling patent cases for generic drugmakers, thanks to what IP practice chair James Hurst calls a “historical quirk.” Former Winston attorneys have gone on to lead such generic drug companies as Barr Pharmaceuticals, Inc.–then tapped their old firm when they needed legal help.
In recent years the firm made a strategic decision to expand its IP practice. This year, that move truly began to pay off. While few firms can credibly argue that their litigation wins affect how we all use the Internet, Winston & Strawn can make that claim–more than once.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
